Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Rating of “Buy” by Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has been given an average rating of “Buy” by the eight brokerages that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $23.43.

A number of brokerages recently weighed in on CLBT. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Craig Hallum increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Friday, February 14th.

Institutional Trading of Cellebrite DI

A number of hedge funds and other institutional investors have recently bought and sold shares of CLBT. Pathway Financial Advisers LLC increased its holdings in shares of Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after acquiring an additional 4,118 shares during the last quarter. Meitav Investment House Ltd. boosted its holdings in Cellebrite DI by 29.7% in the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock valued at $34,797,000 after purchasing an additional 473,293 shares in the last quarter. Pembroke Management LTD increased its stake in Cellebrite DI by 24.3% in the third quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock valued at $32,137,000 after purchasing an additional 372,619 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in Cellebrite DI by 8.3% during the third quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company’s stock worth $861,000 after purchasing an additional 3,912 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Cellebrite DI by 96.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 95,351 shares of the company’s stock worth $1,606,000 after buying an additional 46,727 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Down 1.7 %

CLBT opened at $18.03 on Wednesday. Cellebrite DI has a 52 week low of $10.25 and a 52 week high of $26.30. The business has a fifty day simple moving average of $22.14 and a 200-day simple moving average of $19.69. The firm has a market cap of $3.71 billion, a P/E ratio of -12.97, a P/E/G ratio of 4.27 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Sell-side analysts expect that Cellebrite DI will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.